FDA approved Evusheld injectable as an emergency prophylaxis for COVID-19 aged 12 years and over, with a body weight of at least 40 kg.
On June 29, Dr. Paisan Dankum, secretary-general of the Food and Drug Administration (FDA), said that the FDA has approved the registration of AstraZeneca’s drug “Evusheld” under a license. The condition was in an emergency situation on June 27. Evusheld is a monoclonal antibody drug used to prevent COVID-19, but not for treatment. and is not used to replace immunization from vaccination This drug is available for use in adults and adolescents aged 12 years and over who weigh at least 40 kg. Preliminary information should be given to the doctor, such as a history of drug allergy. History of cardiovascular disease treatment pregnancy and lactation including vaccination history, etc. Evusheld has previously been registered as a drug by both the European Union and the United States.
Evusheld, two long-acting antibodies, tixagevimab and cilgavimab, has been registered for emergency use for pre-exposure prophylaxis of COVID-19 in people aged 12 years and over and weighing at least 40 kg. in the United States in December 2021 and Europe in March 2022. It is useful for people with moderate to severe immunodeficiency who may have a poor immune response to the coronavirus vaccine or who are contraindicated to vaccination. or refuse to vaccinate. The Ministry of Public Health has found that Evusheld can prevent infection with COVID-19, serious illness and death in 3 groups of immunocompromised patients, namely dialysis patients. organ transplant patients and patients with autoimmune diseases in a period of 6 months, but the most cost-effective in dialysis patients Purchasing the drug will use some of the AstraZeneca vaccine quota to convert to such antibodies.